Swiss Dental Startup vVARDIS Begins Trading on NYSE Under VVVV
vVARDIS, a dental biotech targeting cavity treatment without drilling, has gone public on the New York Stock Exchange under the ticker VVVV.
vVARDIS, a dental biotechnology company co-founded by Dr. Haley Abivardi and Dr. Goly Abivardi, began trading on the New York Stock Exchange on Nov. 13, 2026, under the ticker symbol VVVV, marking a significant milestone for a firm that has staked its growth on a drill-free approach to treating tooth decay.
The company's core proposition targets cavities, which the founders describe as the world's most prevalent non-communicable disease, affecting hundreds of millions of people globally. By pursuing a treatment path that eliminates the drill, vVARDIS is positioning itself against decades of conventional dentistry practice and a large, entrenched industry.
Read more Leverage Shares Launches 2x Long Anthropic ETF as ANT Debuts on Nasdaq →
The public listing gives vVARDIS access to capital markets at a moment when investor appetite for health-focused biotechnology remains a significant driver of IPO activity. The NYSE debut signals the company's intent to scale its technology and commercial reach beyond its founding stage.
The Abivardi co-founders, who bring a scientific and clinical background to the venture, have framed the company's mission in public health terms, arguing that the burden of untreated dental disease represents both a humanitarian and a market opportunity. The IPO puts that thesis to the test before institutional and retail investors alike.
Continue reading at All Financial Services & Investing.